Europe vs China Cosmetics Manufacturer: Transfer Guide
Transfer scope mapped against Regulation (EC) No 1223/2009. Timeline from our own transfer projects. View full-size diagram
Most articles comparing a European cosmetics manufacturer with a Chinese one are written for brands that have not started yet. This one is not. It is written for the brand that already produces in Europe — an Italian or Polish private label supplier, a German contract manufacturer, a French filler — and is now working out what it would actually take to move that production to China.
Start with the product information file. The receiving factory supplies its manufacturing method and GMP statement, and the safety assessor checks which test results still represent the product. If your European manufacturer also served as Responsible Person, check whether that service continues under your contract.
We manufacture in Guangzhou and we do take transfer projects, so read our view with that in mind. But the constraints below are set by the regulation and by physics, not by us, and a supplier who tells you a transfer is straightforward is either not reading the same regulation or is planning to leave the awkward parts on your side of the table.
What a Transfer Legally Is
Start with the instrument that governs this. Cosmetics sold in the EU sit under Regulation (EC) No 1223/2009. Article 11 requires that a Responsible Person keep a product information file for every product placed on the market, retained for ten years after the last batch was placed on the market. Critically, the article specifies that the file contains information and data "which shall be updated as necessary."
Article 11(2) identifies the records to review when manufacturing changes. These include the product description, safety report, manufacturing method and GMP compliance statement, evidence supporting claims where justified, and animal testing data. The RP also checks the product’s notification under Article 13.
Read point (c) again, because it is the one that decides how much work a transfer is. The file must describe the method of manufacturing and carry a GMP statement. Those attach to the facility that actually makes the product. When the facility changes, that content is no longer accurate, and an inaccurate PIF is not a paperwork inconvenience — it is the file a competent authority will ask for if a product is questioned.
Ask for the new manufacturing description and GMP statement before commissioning laboratory work. Give the safety assessor the old and proposed process specifications so they can identify which results still apply and where new evidence is needed.
Which Parts of the Safety Report Need Review?
Annex I of the regulation sets out the minimum contents of the cosmetic product safety report. Part A is the safety information; Part B is the assessment. Working through Part A point by point shows precisely which evidence is portable and which is not.
Point 1, composition. If the composition and raw material specifications are unchanged and you have access to the complete formula, the assessor can use the existing composition data. Record any proposed substitution before the first trial batch.
Point 2, stability. The safety report must support the shelf life of the product under foreseeable storage conditions. Compare the original study with the proposed batch size, homogeniser shear, cooling curve, fill temperature and packaging. A change that could affect emulsion stability may call for a new study on representative batches. Ask the assessor to identify the gap.
Point 3, microbiological quality. Compare the water system, process, pack and how consumers use the product. Under the Commission guidance on the safety report, most finished products need microbiological quality and preservation challenge testing. The assessor can justify an exception for a low-risk product. A single-use product or a pack that cannot be opened may need only finished-product microbiological quality testing. Record the scientific justification for the route chosen.
Point 4, impurities and packaging, partly travels. Substance purity data usually holds if you keep the same raw material suppliers. For packaging, the annex asks for information on the material’s purity and stability. If you change the jar, check whether the existing compatibility evidence covers the new material and contact conditions.
Points 5 through 8 largely travel. Normal and foreseeable use, exposure to the product, exposure to the substances, and the toxicological profile of each substance are formula-and-use driven rather than site driven. A margin of safety built on a NOAEL does not change because the factory did.
Have the assessor list the evidence accepted from the old site and the tests needed on the new product and pack. Use that list to compare transfer quotes on the same basis.
| Annex I Part A point | Starting point | Why | What to check or budget for |
|---|---|---|---|
| 1. Composition | Retain if unchanged | Chemical name, INCI, CAS, EINECS/ELINCS and function do not depend on the site | Confirm the formula, specifications and rights to the data |
| 2. Physical and chemical stability | Review existing study | Stability belongs to a batch on given equipment, at a given scale, in given packaging | A new study if the evidence no longer supports shelf life |
| 3. Microbiological quality | Assess preservation and exposure | Water, process and packaging can affect microbial risk | Microbiological and challenge tests as the assessment requires |
| 4. Impurities and packaging | Partly | Substance purity holds if raw material suppliers stay; compatibility is per product-and-component pair | Check the new component and test any evidence gaps |
| 5. Normal and foreseeable use | Retain if use is unchanged | Use-driven, not site-driven | Confirm the use instructions on the new pack |
| 6. Exposure to the product | Retain if exposure is unchanged | Use-driven, not site-driven | Check dispensing, frequency and area of use |
| 7. Exposure to the substances | Retain if concentrations and use are unchanged | Derived from formula and use pattern | Review exposure if the formula or dose changes |
| 8. Toxicological profile | Review against the material specifications | A margin of safety built on a NOAEL does not change because the factory did | Check toxicological data for any new grade or impurity |
Ask the lab which studies can run together. If the assessor calls for a new stability study, its duration may determine your first shipment date.
The Responsible Person Trap
This is the part brands miss most often, and it is worth being blunt about because it can strand a launch.
Article 4 requires that only cosmetic products for which a legal or natural person is designated within the Community as Responsible Person may be placed on the market. The allocation then depends on where manufacturing happens. Article 4(3): for a product manufactured within the Community and not subsequently exported and reimported, the manufacturer established within the Community is the Responsible Person. Article 4(4): where such a manufacturer is established outside the Community, it must designate, by written mandate, a person established within the Community who accepts in writing. Article 4(5): for an imported cosmetic product, each importer is the Responsible Person for the product he places on the market, and may by written mandate designate an EU-established person who accepts in writing.
Follow the consequence. While you produced in Italy, your Italian manufacturer may have been your Responsible Person by operation of Article 4(3) — possibly without either of you treating it as a separate service, because the law assigned it. The moment production moves to China, your product becomes an imported cosmetic product and Article 4(5) applies instead. Your factory in Guangzhou cannot be your Responsible Person. It is not established in the Union, and no contractual language changes that.
Identify the EU importer responsible for the imported product and check any existing RP contract. The importer may designate an eligible person who accepts the mandate in writing. Agree who maintains the file, handles the notification and appears on the label before printing.
The same logic sits behind the wider set of obligations for a European private label project, which is worth reading alongside this if the RP question is new to you. For an imported product, confirm who will hold each legal role.
Does a Transfer Make It a New Product?
Brands ask this hoping the answer is a clean no, and the useful answer is that it depends on what you keep identical.
Article 13 requires the RP to notify details such as the name and category of the product, the RP’s name and address, and the country of origin for imports. If the same RP continues, it must update changed particulars without delay. If EU-made and Chinese-made versions of the same product are marketed concurrently, the Commission’s CPNP guide calls for separate notifications for the domestic and imported versions.
If another organisation takes over as RP, the outgoing organisation can copy the notification to it. The recipient gets a draft with a new CPNP reference and must complete the record, including contact and label information, then notify. The earlier record remains with the outgoing organisation. Before printing the imported product’s packaging, check the RP name and address and the Chinese country-of-origin marking against the intended notification. See the European Commission’s CPNP Article 13 user guide.
If the new factory proposes a different raw material grade or emulsifier, give the assessor both specifications. The assessor can determine whether composition, exposure, toxicology or claim support changes. The RP can then determine what needs updating in the safety file and notification.
Which gives you a practical rule for briefing a transfer: demand a reproduction, not an interpretation. Ask the receiving factory to state, in writing and per raw material, whether it will use the identical grade from the identical supplier, and where it cannot, to flag it before sampling rather than after. A factory that cannot answer at that resolution is not ready to take your transfer.
A Sample Timeline for Moving a Single SKU
This example assumes one SKU and a new accelerated stability study. Confirm the applicable tests, approved packaging, first production slot and freight booking before setting a launch date.
Weeks 1 to 3, handover and gap review. Formula, raw material specifications with supplier names and grades, current stability protocol and results, current preservation data and any challenge test or documented justification, packaging drawings and component sources, plus the existing safety report. The output is a gap list: what is missing, what has to be re-run, what raw material substitution risk exists.
Weeks 3 to 7, lab reproduction and side-by-side sampling. The receiving lab makes the product to your existing specification, and you assess it against retained samples from the incumbent. Insist on side-by-side rather than sequential assessment; sensory drift is very hard to judge from memory.
Weeks 7 to 19 in a transfer that needs new testing. For example, a twelve-week accelerated stability study and a preservation challenge test can run in parallel. Ask the assessor to confirm which tests apply, the batches and packs to test, and the earliest date the results will support release.
Weeks 14 to 20 in this example, file and notification work. Update the safety report, manufacturing method and GMP statement. The RP checks the import origin and handles the notification for the agreed RP arrangement. Some documentation can be prepared while the test results are pending.
From week 20 in this example, production and shipping. Confirm the release date with the factory and obtain a current port-to-port sailing estimate, including time for clearance and onward delivery.
Five to six months from decision to landed stock is a planning estimate for a straightforward single SKU. Retained evidence, new studies, component availability and transport can all change that estimate.
What a Transfer Costs, and Where the Money Actually Goes
The reason brands transfer is unit cost, and the reason transfers stall is that the one-off cost of moving is underestimated. Both things are true at once.
Compare the recurring landed cost at your actual order size with the one-off cost of moving. Ask the receiving factory, assessor and importer to identify who charges for each of the following items.
- Re-testing. Price the stability, preservation and compatibility work the assessor identifies for each SKU.
- Safety assessor time. Your assessor has to revisit the report. If composition held and only the manufacturing sections changed, this is an update. If raw materials were substituted, it is closer to a reassessment.
- Responsible Person arrangements. If an RP service was bundled in your old contract, confirm whether the importer will take the role and whether anyone will charge a separate service fee.
- Dual inventory during changeover. If you need stock from both sites during the handover, calculate the overlap and carrying cost using your sales forecast.
Set against that, the structural differences that made you consider moving in the first place do not disappear:
Minimum order quantity runs the other way. This is the honest counterweight. European private label suppliers routinely quote minimums in the 100 to 500 unit range. Asian factories generally work in the thousands; our standard minimum is 3,000 units per SKU for skincare, body, hair care, fragrance, and essential oils, while sheet masks and other specialist formats can run higher. If your European MOQ is what has been keeping your inventory risk low, a transfer increases that risk, and for a brand still testing demand that can outweigh a unit cost gain entirely.
Country of origin becomes a label element. Origin marking applies to imported product, and in some European retail channels and premium positions the origin statement affects reception. Whether that matters is a positioning judgement only you can make. We are not going to pretend it never matters.
Freight and lead time enter your planning. Sea freight sits on top of production time and has to be planned around rather than compressed. Brands moving from a two-week domestic replenishment cycle to an ocean cycle need to rebuild their forecasting before they need to rebuild their formula.
Where the move pays back most reliably is at volume, across multiple categories, and when you are also expanding beyond Europe. If you are producing skincare in Italy and later want body care and hair care under one roof, and you are also entering Southeast Asia or the Gulf, one factory assembling a single technical data set that serves several markets removes duplicated work. If Europe is your only market and you sell 400 units a month, the arithmetic probably does not favour a transfer, and a supplier who tells you otherwise is selling.
What a Transfer Actually Demands of the Receiving Factory
Everything above describes the work. This section is about who can do it, because a transfer asks a factory for something a normal private label order never does: reproduce someone else's product without the person who made it.
That is a reverse engineering problem, and it is where most transfers fail. Three capabilities decide the outcome, and they are worth checking in any factory you are considering, ours included.
Formulation headcount, because reverse engineering is not a catalogue task
Formulation lab, Guangzhou · where a transferred formula is rebuilt and compared side by side with retained incumbent samples.
A normal private label project starts from a factory's existing formula. A transfer starts from someone else's finished product plus a specification sheet, and the receiving lab has to close the gap between them — matching texture, viscosity build, scent behaviour, colour, absorption and cushion, not just the ingredient list. Two products with identical INCI declarations can feel entirely different, and your customers will notice long before your spreadsheet does.
That work is bounded by the formulation resources assigned to it and how long the team can iterate. We handle transfer projects through an in-house R&D function connected to the production site. Buyers should compare the named technical team, transfer protocol, sample evidence, and line trial plan rather than assuming capability from an unverified headcount comparison.
The question to ask any receiving factory is not "can you make this" but "how many formulators will be assigned, and how many iteration rounds are included before we are quoting extra." A factory that cannot answer that in numbers is going to hand your transfer to whoever is free.
Raw material access, which is where transfers quietly die
Raw material store · actives bought direct from BASF, Symrise, Croda and Dow Corning, so a transfer can keep the same grade rather than substitute.
This is the failure mode we see most often, and it is worth understanding before you sign anything.
Ask the new factory to confirm the grade and supplier against the original specifications. If it proposes an alternative, compare the composition, impurity profile and functional specifications with your assessor before deciding whether formula trials or safety-file updates are needed.
Whether that happens is decided by supplier relationships, not by good intentions. We buy directly from BASF, Symrise, Croda, Dow Corning, SEPPIC, Lubrizol, Shin-Etsu and DSM. Most European formulas built on premium actives are built on exactly these houses, which means in the majority of transfers we are buying the same material from the same producer rather than sourcing a local equivalent and hoping the sensory profile survives. Where we genuinely cannot match a grade, we flag it in week two with the reason, rather than at sampling when you have already committed.
Ask your candidate factory for its raw material sources by name. A factory buying premium actives through trading intermediaries cannot promise you grade continuity, because it does not control the chain.
Line matching, so your formula is not forced onto whatever equipment is free
Vacuum emulsifying unit · homogeniser shear and heating and cooling curves are what a transferred emulsion has to be matched against.
Stability behaviour follows the process: homogeniser shear, heating and cooling curves, vacuum conditions, fill temperature. Reproducing an emulsion faithfully means matching that process, which requires having a line whose profile can be matched in the first place.
We run 13 production lines with capacity of over 200,000 units a day across skincare, body care, hair care and aromatherapy. The practical benefit in a transfer is choice: we select the line that fits your process rather than adapting your formula to the one line we have. A single-line facility cannot offer that, and the adaptation always lands on the formula.
One of 13 filling and assembly lines · line choice is what lets a transferred process be matched instead of the formula being adapted.
Category breadth matters here too if you are moving a range. Skincare, body care and hair care under one roof means one transfer project, one quality baseline and one set of documentation, instead of three parallel transfers to three suppliers with three sample cycles. In practice that means an emulsion like a centella repair cream, a niacinamide body lotion and a silk repair conditioner can move on one timeline against one set of stability protocols.
Want these three answers in writing before you commit?
Send us the product you currently make in Europe and we will come back with the formulators assigned and iteration rounds included, a per-raw-material position on whether we can buy your exact grades, and which of our lines matches your process — with any grade we cannot match flagged up front rather than at sampling.
The quality system position, stated plainly
In-process quality check · the GMP position that Article 11(2)(c) requires to be stated in the file for the actual manufacturer.
Article 11(2)(c) requires the file to carry a GMP compliance statement for the actual manufacturer, so this is a document requirement rather than a marketing point. We hold ISO 22716:2007 cosmetics GMP under certificate HBPCER20260352 and GMPC under HBPCER20260353, both issued by Intertek on 16 July 2026 and valid to 15 July 2029, verifiable by anyone at certs.intertek.com.cn. For a later US launch, our third-party facility statement identifies the site by FEI 3038966060 and lists 29 July 2028 as the biennial renewal date. Ask for the current registration status separately.
We publish the numbers rather than describing the certificates because the check is the point. Certification is table stakes for any factory worth transferring to — it gets a supplier onto your shortlist, it does not distinguish them on it. The three capabilities above are what actually determine whether your transfer produces the same product.
The Case for Treating a Transfer as an Upgrade Window
Here is the argument most brands miss, and it changes the economics of the whole decision.
If you are considering a formula change as well as a transfer, ask the assessor to compare two scenarios. Reproducing the current product may let you retain relevant evidence. Changing ingredients, their delivery or their levels can add new safety, stability or claim-support work.
Price the two routes separately. Where both need a line trial or stability study, the lab can advise what work they can share and where an additional test batch is necessary.
What that upgrade can be depends on the factory. We are authorised to apply a licensed portfolio of supramolecular delivery patents in our production, covering areas including PDRN delivery, supramolecular self-assembly carriers, Ectoin stabilisation systems, S-Pro-Xylane formulation technology, exosome encapsulation, freeze-dried active preservation, microneedle patch delivery and transdermal peptide delivery. If a new delivery system is proposed, ask the assessor which additional safety, stability and claim-support work that particular system requires. Freeze-dried preservation is the clearest example, because it changes the format rather than the declared active — our firming freeze-dried serum set keeps the active out of water until the moment of use, which is a shelf-life argument a liquid version cannot make.
Two concrete patterns from transfer projects:
- Keeping the active and changing its carrier. Check the new carrier ingredients, their concentrations and their effect on exposure. Have the assessor review the formula and check the ingredient declaration and evidence for any proposed performance claim.
- Reformulating for a second market while you are at it. If you are transferring partly because you are expanding beyond Europe, the same lab pass can adjust the formula for a hot and humid climate or a different regulatory annex. Ask the lab which stability data cover the intended storage conditions and price any additional trials for the second market.
We should be precise about what we are and are not claiming. These are licensed technologies we are authorised to apply in manufacturing, not efficacy guarantees, and any performance change has to be evidenced per project through the same testing as anything else. Ask what extra evidence the proposed change needs before including it in the transfer budget. Our delivery technology platform sets out the areas in detail.
This is also the honest answer to "why transfer at all if unit cost is the only gain." For a brand at low volume selling only into Europe, unit cost alone probably does not justify the move. Unit cost plus a formula improvement plus documentation that also serves ASEAN, the Gulf or the US is a different proposition, and it is the scenario in which a transfer can become commercially worthwhile.
When We Tell Brands Not to Transfer
Four situations where we advise waiting, stated briefly because they are quick to check. You do not own your formula — some European suppliers work from their own catalogue formulations, in which case there is nothing to transfer and you are looking at a development project instead; check your agreement first, because this changes the scope completely. Your annual volume sits below the MOQ ladder — if 3,000 units is more than roughly a year of sales for that SKU, you will tie up cash and risk shelf life, so grow into it. You are mid-way through a retail listing or rebrand — continuity of supply expectations and transfer risk should not overlap. You need it in eight weeks — confirm the assessor’s testing plan first. If a twelve-week study is needed, an eight-week launch leaves too little time to complete it.
Considering a move from a European supplier?
Send us your current formula scope, SKU count, annual volume and target market. We will come back with a gap list and an honest read on whether a transfer is worth it for your volume — including if the answer is no.
Frequently Asked Questions
Can my Chinese factory be my EU Responsible Person?
No. Article 4 requires the Responsible Person to be a legal or natural person established within the Community, and Article 4(5) makes the importer the Responsible Person for an imported cosmetic product unless it designates another EU-established person by written mandate accepted in writing. A factory in Guangzhou cannot hold the role. Your options are your own EU entity, your importer or distributor, or a specialist RP provider.
Do I need a new CPNP notification when I change manufacturer?
If the RP continues, it must update changed Article 13 particulars without delay, including the country of origin when production moves to China. If another organisation takes over as RP, it must notify under its own responsibility. A copied CPNP record arrives as a draft with a new reference. If both imported and EU-produced versions are supplied at the same time, notify the versions separately.
Can the new factory use the stability data from my European supplier?
Give the safety assessor the European study and a comparison of the formula, new manufacturing process, scale and final pack. The assessor can retain results that still represent the product or ask for targeted testing where conditions have changed. For preservation, document the microbial risk and the scientific basis for any exception to challenge testing.
How long does a transfer really take?
Allow roughly five to six months from decision to landed stock for a straightforward single SKU as a starting estimate. A new twelve-week stability study, if needed, can set the pace. Confirm the file updates, test schedule and freight booking before fixing the launch date.
What if my European supplier owns the formula?
Then there is nothing to transfer and you are looking at a development project instead: a new formula built to match your product's performance and sensory profile, with its own sampling and testing timeline. Check your existing agreement before budgeting for a transfer, because this changes the scope completely.
Is it cheaper to keep one SKU in Europe and move the rest?
Sometimes, and it is an underused option. Split sourcing lets you keep a low-volume or launch-critical SKU on short domestic lead times while moving the volume lines where unit cost actually matters. The cost is two supplier relationships and two quality baselines, so it suits ranges where volume is unevenly distributed across SKUs.
The Short Version
Update the manufacturing method and GMP statement for the new site. Have the assessor check whether the stability and preservation evidence still represents the product in its final pack. Before printing, confirm the imported origin and RP details on the label. The RP handles the relevant CPNP update or new notification.
For an initial one-SKU plan, estimate the time and cost of any tests the assessor identifies, a trial on the proposed line, the file update, transport and any stock overlap. Ask for written confirmation of the raw material grades before sampling.
If you want to change the formula during the move, ask for a separate quote for the extra assessment and test work. Compare it with the cost of an unchanged transfer before booking production or committing to a new launch claim.
Ready to Start Your Project?
Tell us your product requirements. Within 24 hours, our technical team will reply with a quotation or the questions needed to prepare one.